Opexa Therapeutics, Inc. (NASDAQ:OPXA)

Fast Track status just announced by the FDA for its multiple sclerosis drug, Tovaxin. It is currently in Stage IIb of clinical trials, thus far showing effectiveness where other drugs have failed. Namely treating SPMS - Secondary Progressive Multiple Sclerosis. It also is thus far effective in treating Relapsing Remitting MS. Thus, it's a potential double winner in combating the early and secondary form of the disease. “The TERMS trial was a landmark study in that it was the first time that a personalized immunotherapy of this nature was used to treat MS patients,” commented Edward Fox, MD, PhD, director of the MS Clinical of Central Texas, and a principal investigator in the TERMS study. “The results were encouraging in that they supported the continued development of Tovaxin in both relapsing remitting and secondary progressive MS.”

Options Predictor Rank #18 on 9/11/11. P/C Ratio 0.029 and Call Sizzle 3.605.